Non-pharmacological approaches are preferred for promoting sleep in the ICU; however, limited but growing evidence supports the use of pharmacological agents.

Suvorexant belongs to a new class of sleep medications called dual orexin receptor antagonists. Orexin is a molecule that promotes wakefulness; suvorexant blocks it, promoting deeper sleep.

A study from Washington University in St. Louis found taking suvorexant, a common insomnia medication, for two nights slightly decreased amyloid-beta and tau proteins linked to Alzheimer's ...

Recently, a study has shed light on the potential of suvorexant, a drug commonly used to treat insomnia, as a possible tool in the fight against Alzheimer's disease. This finding s ...

Scientists have developed several treatments for sleep maintenance insomnia. These include cognitive behavioral therapy and medication. Avoiding nighttime drinking, especially caffeine and alcohol ...

Suvorexant dose should be reduced to 5 mg when used along with anti-viral medicines like amprenavir, atazanavir, antibiotics like ciprofloxacin, erythromycin, antifungal medicines like fluconazole ...

More information: Kotaro Hatta et al, Suvorexant for Reduction of Delirium in Older Adults After Hospitalization, JAMA Network Open (2024). DOI: 10.1001/jamanetworkopen.2024.27691 ...

Consistent with expectations, suvorexant showed a trend toward reducing delirium, with only 16.8% of participants exhibiting delirium compared to 26.5% in the placebo group.

Consistent with expectations, suvorexant showed a trend toward reducing delirium, with only 16.8% of participants exhibiting delirium compared to 26.5% in the placebo group.

Suvorexant was also linked to significantly lower delirium rates than was placebo in a post hoc analysis of patients with hyperactive plus mixed subtypes of dementia (10.9% vs 21.6%; P = .04).

The study, published in JAMA Network Open, found that 17% of participants taking suvorexant developed delirium compared with 27% in the placebo group.

According to results, those in the 20 mg suvorexant treatment group registered acutely decreased levels of CSF amyloid beta (A-beta 38/40/42), whereas those given 10 mg suvorexant had a much more ...